AzTrials
AzTrials

CholangiocarcinomaNCT06369480

Prognostic Factors for Survival in Patients With Cholangiocarcinoma

An observational study of Cholangiocarcinoma, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aim to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. Read more about this study

Who is it for?
Any age
Conditions the study is for
Cholangiocarcinoma
What is being tested?
Resection/Ablation of tumor, Palliative chemotherapy and Neoadjuvant chemotherapy
Type of treatment
Surgery or procedure
How many people
2,000 participants
Where
1 siteDenmark
Study dates
1 Feb 2024to 31 Aug 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients identified in the Danish Liver-Biliary Cancer Database with a confirmed diagnosis of cholangiocarcinoma registered from 2013 to 2020.

Who may be able to join

  • Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020.

Who cannot join

  • We will exclude from the analysis all records with more than one interventions. Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting will be also excluded, as well those with inconsistent data regarding date of reference to the MDT.

Trial locations and contacts

1 site in 1 country.

Hans-Christian Pommergaard, M.D./Ph.D contact

35458519

hans-christian.pommergaard@regionh.dk

Denmark1 site, 1 recruiting
  • Rigshospitalet

    Copenhagen, 2100

    Hans-Christian Pommergaard, MD DMSc PhD, hans-christian.pommergaard@regionh.dk

    Recruiting

Other trials in Denmark

About this study

The objective of this retrospective study is to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aim to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.

Read the detailed description

BACKGROUND

Cholangiocarcinoma (CCA) is a highly aggressive neoplasia and is considered the second most common primary liver cancer (1). Its global mortality has shown an upward trend over the last two decades (2), with a survival rate of less than 5% at 5 years. The poor prognosis is related to late-stage detection since CCA can be asymptomatic in its early stages (3). In Denmark, the estimated cumulative risk of mortality due to CCA was 0.74 for men (ranking 20th in all of Europe) and 0.34 for women (ranking 6th in Europe) (4).

CCA is anatomically classified into three groups: intrahepatic, perihilar, and distal CCA (1,2). Additionally, CCA can be classified as mass-forming, periductal infiltrating, and intraductal based on tumor location, which may be associated with tumor morphology (3). A precise anatomical classification of CCA in each case is essential for accurately assessing potential complications (1).

The diagnosis, staging, and treatment of CCA can be challenging and are typically performed by a multidisciplinary team (MDT) of specialists. MDT meetings are a common practice in cancer care aimed at improving survival. However, it is important to note that there are currently no standardized recommendations for MDT practices in CCA (2). Recently, authors have made efforts to identify areas of improvement and establish standard guidelines for MDT decisions based on the current practices of specialized European teams with expertise in CCA. According to the recommendations of the European Network for the Study of Cholangiocarcinoma, international guidelines should be utilized for MDT decisions. However, preference for national guidelines should be given (2) Nevertheless, at the moment, there are not in Denmark a national guideline to determine the most optimal treatment for CCA patients based on local statistics.

Hence, the objective of this retrospective study was to determine the survival rates of CCA patients based on different therapeutic approaches. Additionally, we aimed to investigate the risk factors associated with poor survival within a cohort of patients treated over a seven-year period across four Danish hospitals. We anticipate that our findings could provide additional evidence for clinical decision-making, improve patient outcomes, and contribute to the knowledge in the field.

AIMS AND HYPOTHESIS

Aim I Determine the survival rates of CCA patients based on various therapeutic approaches following the MDT decision.

Aim II Determine the risk factors associated with unfavorable overall survival in CCA patients.

Hypothesis Advanced age, male gender, poor performance status, non-operability, lack of tumor resectability, and being treated in a hospital where the MDT decision is made all pose as poor survival risk factors for CCA patients. In contrast, we anticipate a better prognosis for patients undergoing curative treatment (surgery) compared to non-surgical treatments. Finally, our hypothesis suggests that chemotherapy provides a better prognosis than no treatment in CCA patients.

KEY DATA SOURCES

Primary data sources Patients will be identified in the Danish Liver-Biliary Cancer Database and data was retrieved retrospectively from medical records in individual centers. The Danish Data Protection Agency (p-2023-14848) has approved the study.

Inclusion criteria Patients' eligibility for this study is contingent on a diagnosis of CCA confirmed by the MDT from Aalborg Universitetshospital, Aarhus Universitetshospital, Odense Universitetshospital, and Rigshospitalet in Denmark from 2013 to 2020.

Exclusion criteria We will exclude from the analysis all records resulting from more than one intervention (on the same patient). Additionally, all patients whose cholangiocarcinoma diagnosis was canceled following the MDT meeting were also excluded, as well those with inconsistent data regarding date of reference to the MDT.

DEFINITION OF PRIMARY OUTCOMES Overall survival will be defined as the period from the initial diagnosis of the disease to the registered date of death, regardless of the cause. The disease diagnosis will be determined from the date of MDT referral, and the date of death will be based on the information provided in the Danish Civil Registration (CPR) number.

STATISTICAL ANALYSIS Patient baseline characteristics were described using the mean and standard deviation (SD) for continuous data and frequency and percentage for categorical data. Differences between treatment plan groups in variables with a normal distribution were analyzed with an ANOVA test. Non-normally distributed data were analyzed with Kruskal-Wallis test and presented as medians and interquartile ranges. Overall survival was calculated from the date of referral to the MDT to the date of death reported in the Danish Civil Registration (CPR) number. Survival analysis was conducted using the Kaplan-Meier estimator with a 95% confidence interval. The analysis of risk factors associated with CCA patients' survival was performed using univariate Cox regression analysis. Significance was considered when the P-value was <0.05. All analyses were conducted using SPSS version 29.0.01.1 (171).

Being tested
Resection/Ablation of tumor, Palliative chemotherapy, Neoadjuvant chemotherapy, Stereotatic radiotherapy, Best supportive care
Keywords
Cholangiocarcinoma, Survival, Surgery, Treatment
Medical subject headings
Cholangiocarcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Resection/Ablation of tumorProcedure or surgery

    Also called Surgery

    Curative treatment

  • Palliative chemotherapyProcedure or surgery

    Also called Chemotherapy

    Chemotherapeutic medications

  • Neoadjuvant chemotherapyProcedure or surgery

    Also called Adjuvant chemotherapy

    Chemotherapeutic medications after surgery

  • Stereotatic radiotherapyProcedure or surgery

    Also called Radiotherapy

    Radiotherapy

  • Best supportive careProcedure or surgery

    Also called Supportive care

    Symptomatic treatment, non-curative treatment

Study groups in NCT06369480
Study groupRoleWhat they receive
CholangiocarcinomaPatients with diagnosis of Cholangiocarcinoma confirmed by MDT
Receives: Procedure: Resection/Ablation of tumor; Procedure: Palliative chemotherapy; Procedure: Neoadjuvant chemotherapy; Procedure: Stereotatic radiotherapy; Procedure: Best supportive care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Aim I

    Determine the survival rates of CCA patients based on various therapeutic approaches following the MDT decision.

    Measured: 6 months

  2. Aim II

    Determine the risk factors associated with unfavorable overall survival in CCA patients.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Apr 2024
  2. Study start1 Feb 2024
  3. Primary completion31 Aug 2024 (estimated)
  4. Study completion31 Aug 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
2,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06369480
Sponsor's protocol ID
Journal-nr.: R-23057752
Status last verified
Apr 2024
First submitted
11 Apr 2024
Last updated
17 Apr 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Tawarungruang C, Khuntikeo N, Chamadol N, Laopaiboon V, Thuanman J, Thinkhamrop K, Kelly M, Thinkhamrop B. Survival after surgery among patients with cholangiocarcinoma in Northeast Thailand according to anatomical and morphological classification. BMC Cancer. 2021 May 3;21(1):497. doi: 10.1186/s12885-021-08247-z.

    PubMed 33941120
  • Thuehoj AU, Andersen NC, Worm ES, Hoyer M, Tabaksblat EM, Weber B, Mortensen HR. Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta Oncol. 2022 Feb;61(2):197-201. doi: 10.1080/0284186X.2021.1995893. Epub 2021 Nov 2. No abstract available.

    PubMed 34726565
  • Cillo U, Fondevila C, Donadon M, Gringeri E, Mocchegiani F, Schlitt HJ, Ijzermans JNM, Vivarelli M, Zieniewicz K, Olde Damink SWM, Groot Koerkamp B. Surgery for cholangiocarcinoma. Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089.

    PubMed 30843343
  • Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023 Mar;73(2):198-222. doi: 10.3322/caac.21759. Epub 2022 Oct 19.

    PubMed 36260350
  • Li Y, Song Y, Liu S. The new insight of treatment in Cholangiocarcinoma. J Cancer. 2022 Jan 1;13(2):450-464. doi: 10.7150/jca.68264. eCollection 2022.

    PubMed 35069894
  • Ma KW, Cheung TT, Leung B, She BWH, Chok KSH, Chan ACY, Dai WC, Lo CM. Adjuvant chemotherapy improves oncological outcomes of resectable intrahepatic cholangiocarcinoma: A meta-analysis. Medicine (Baltimore). 2019 Feb;98(5):e14013. doi: 10.1097/MD.0000000000014013.

    PubMed 30702559

Questions about this trial

What is this clinical trial studying?

An observational study of Cholangiocarcinoma, run by Copenhagen University Hospital, Rigshospitalet at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hans-Christian Pommergaard, M.D./Ph.D (35458519, hans-christian.pommergaard@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Aim I (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06369480, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2024; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in